Mathai Mammen, SVP, Research & Early Clin Development at THERAVANCE INC (THRX), sold 7,000 shares at $36.51 ($256K) on 2013-07-30, disclosed to the SEC on 2013-08-01.
Scheduled sale ($256k) by SVP, Research & Early Clin Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| THRX | SELL | 2013-05-02 | $236K | — | Filing → |
| THRX | SELL | 2013-02-22 | $155K | — | Filing → |
| THRX | SELL | 2012-11-06 | $150K | — | Filing → |